Comparative Hypertensive Trials Preferred Endpoint Is Systolic BP, Cmte Says
Executive Summary
The primary efficacy endpoint in comparative antihypertensive trials should shift from diastolic blood pressure measured at trough levels to systolic blood pressure at trough, FDA's Cardiovascular & Renal Drugs Advisory Committee member Steven Nissen, MD, suggested July 18
You may also be interested in...
Atacand Label May Note 2 mm Hg BP Reduction Over Cozaar, Cmte. Says
AstraZeneca's Atacand labeling may claim a 2 mm Hg reduction in diastolic blood pressure over Merck's Cozaar, FDA's Cardiovascular and Renal Drugs Advisory Committee said July 18
King Altace sNDA Submitted For Five Indications; 4th Quarter Sales Grew 46%
King submitted an Altace (ramipril) sNDA Jan. 18 for the significant reduction of mortality, myocardial infarction, stroke, revascularization procedures and heart failure in patients at risk for such events.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011